Embecta Corp.

NASDAQ:EMBC

Drug Manufacturers - Specialty & Generic

Healthcare
$6.09 +0.65%

+$0.02 today

Market cap
$345.06M
Beta
0.81
P/E (TTM)
1.6
EPS (TTM)
$1.92
Dividend yield
14.79%
52W Low $2.77High $15.55

Volume 0.72M

Average 1.95M

EMBC Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Embecta Corp.NASDAQ: EMBC

Research & Development · Q2 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q2 FY2026 research & development of $9.7M rose 162.2% year over year, ahead of the -65.5% change in trailing-twelve-month research & development. Sequentially, it rose 3133.3% from the prior quarter. Over 3 fiscal years it compounded at -30.8% a year.

Context

  • Research & development amounted to 2.0% of revenue in FY2025, down 5.0 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +162.2% holds above the trailing-twelve-month pace of -65.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.7M+3133.3% QoQ
Last fiscal yearSep 2025
$21.5M-72.7% YoY
LTMMar 2026
$18.4M-65.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+162.2%——
1 year-72.7%——
3-year CAGR-30.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
21.5M USD
Year-over-year change
-72.7%
4-year CAGR
-23.6%

Research & Development vs competitors

How EMBC compares with its peers on the latest reported figures

  • EMBC's LTM Mar 2026 research & development of $18.4M is the 9th highest of the 11 companies compared; the peer median is $66.01M.
  • Its year-over-year change of -65.5% is the lowest of 10, against a peer median of -2.5%.
  • Research & development amounts to 1.8% of revenue for EMBC, versus a peer median of 24.7%.
EMBC Competitors Peer median
Research & Development for EMBC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SIGASIGA Technologies, Inc.LTM Mar 2026$2.7T +25130615.4%-33.8%2884018.5%
VIRVir Biotechnology, Inc.LTM Mar 2026$446.24M -15.0%-3.0%681.3%
PRMEPrime Medicine, Inc.LTM Mar 2026$154.18M -2.5%+22.8%3822.0%
MYGNMyriad Genetics, Inc.LTM Mar 2026$106.4M -7.7%+7.7%12.8%
CDNACareDx, IncLTM Jun 2026$79.87M +15.1%-7.5%17.4%
PSNLPersonalis, Inc.LTM Mar 2026$52.16M +6.9%-8.2%80.9%
EBSEmergent BioSolutions Inc.LTM Mar 2026$49.1M -30.6%-34.1%7.3%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$21.15M +13.2%+8.3%10.1%
EMBCEmbecta Corp.LTM Mar 2026$18.4M -65.5%-30.8%1.8%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$16.04M -18.6%-0.6%31.9%
EVHEvolent Health, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding EMBC) $66.01M-2.5%-3.0%24.7%

Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue1.17B1.13B1.12B1.12B1.08B
Cost of Revenue365M354.6M370.9M394.2M400.9M
Gross Profit800M774.9M749.9M728.9M679.5M
Gross Margin68.7%68.6%66.9%64.9%62.9%
Research & Development63M65M85.2M78.8M21.5M
Selling, General & Admin240.3M294.8M341.3M365.1M331.4M
Operating Expenses308M396.8M520.3M554.7M350.2M
Depreciation & Amortization38M31.7M32.7M42.5M51.1M
EBITDA533M334.5M245.4M199M294.7M
EBITDA Margin45.8%29.6%21.9%17.7%27.3%
Operating Income492M378.1M229.6M174.2M329.3M
Operating Margin42.2%33.5%20.5%15.5%30.5%
Interest Income00000
Interest Expense046.2M107M112.3M107.3M
Other Income / Expenses3M(121.5M)(123.9M)(130M)(193M)
Income Before Tax495M256.6M105.7M44.2M136.3M
Pre-Tax Margin42.5%22.7%9.4%3.9%12.6%
Income Tax Expense80M33M35.3M(34.1M)40.9M
Net Income414.8M223.6M70.4M78.3M95.4M
Net Margin35.6%19.8%6.3%7.0%8.8%
EPS (Basic)7.313.921.231.361.64
EPS (Diluted)7.313.891.221.341.62
Weighted Avg Shares56.8M57.06M57.24M58.43M58.31M
Weighted Avg Shares (Diluted)56.8M57.06M57.76M58.33M58.92M

Embecta Corp.

NASDAQ:EMBC

Intrinsic Alpha fair value

Locked

Current Price

$6.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.